This is a summary of the European public assessment report (EPAR) for Aprovel. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Aprovel.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. Treatment of renal disease in patients with hypertension and type-2 diabetes mellitus as part of an antihypertensive medicinal-product regimen.
Therapeutic Area (MeSH)
ATC Code
C09CA04
ATC Item
irbesartan
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| irbesartan | N/A | 厄贝沙坦 |
EMA Name
Aprovel
Medicine Name
Aprovel
Aliases
N/ANo risk management plan link.
